LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

Company Overview

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $9.56 to $9.75
• 50-Day Range: $8.00 to $9.83
• 52-Week Range: $6.40 to $10.00
• Volume: 47,390 shs
• Average Volume: 135,566 shs
• Market Capitalization: $441.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LogicBio Therapeutics Stock Analysis - MarketRank™

LogicBio Therapeutics scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for LogicBio Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LogicBio Therapeutics is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LogicBio Therapeutics is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LogicBio Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.05% of the float of LogicBio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LogicBio Therapeutics has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LogicBio Therapeutics has recently decreased by 3.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LogicBio Therapeutics does not currently pay a dividend.

Dividend Growth

LogicBio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for LOGC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/09/2025
• Today: 6/10/2026
• AGM 2026: 6/11/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Retail/Wholesale
• Industry: Catalog & mail - order houses
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LOGC
• CIK: 1664106
• Web: www.logicbio.com
• Phone: (617) 245-0399
• Fax: N/A
• Employees: 62
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29 million
• Net Margins: N/A
• Pretax Margin: -156.79%
• Return on Equity: -1.73%
• Return on Assets: -1.22%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.67
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $43 million
• Price / Sales: 10.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: 1.95

Miscellaneous

• Outstanding Shares: 45,730,000
• Free Float: 26,309,000
• Market Cap: $441.75 million
• Optionable: No Data
• Beta: 2.09